Request Demo
US FDA accepts review of argenx’s VYVGART Hytrulo for CIDP
20 Feb 2024
Priority ReviewNDAClinical Result
The treatment offered a 61% reduction in relapse risk compared with those who received a placebo. Credit: THICHA SATAPITANON/Shutterstock.com.
The US Food and Drug Administration (FDA) has accepted for priority review Argenx‘s sBLA for VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) to treat chronic inflammatory demyelinating polyneuropathy (CIDP).
A decisFood and Drug Administration (FDA)ator under the Prescription Drug User Fee Act is antVYVGART HytruloJuefgartigimod alfachronic inflammatory demyelinating polyneuropathy (CIDP)
The sBLA submission is based on findings from the ADHERE study, currently the largest clinical trial conducted for CIDP.
It assessed the efficacy and safety of subcutaneous doses of VYVGART Hytrulo in adults.
The trial met its primary endpoint.VYVGART Hytrulo
See Also:Singapore HSA accepts AffaMed’s NDA for ocular treatment
VYVGART Hytrulo treatment offerAffaMed% reduction in relapse risk compared with placebo.
In Stage A of the open-label trial, 67% of participants exhibited evidence of clinical improvement.
VYVGARTnificance of immunoglobulin G autoantibodies in CIDP’s pathology was underscored by the trial’s findings, given VYVGART Hytrulo’s mechanism as an FcRn [neonatal crystallisable fragment receptor] blocker.
The safety profile of the therapy was consistent with previous clinical trials and its established profile, and it was found to be well-tolerated.
Following the completion of the ADHERE study, 99% of elCIDPle patients opted to continue treatment in the ADHERE-+ openVYVGART Hytrulon study.
Luc Truyen, argenx chief medical officer, stated: “The announcement brings us one step closer to delivering the transformative innovation of VYVGART Hytrulo to CIDP patients.
“We chose to use a priority review voucher to accelerate the review of our submission because CIDP patients have long been waiting for new treatment options.
“FDA’s acceptance of the sBLA represents an important milestone in our continued drive to bring novel treatments for rare autoimmune diseasesVYVGART Hytruloant CIDP forward for people whose lives have been profoundly impacted by this devastating disease.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.